Recent activity at Kansas Department of Health and Environment
Meetings, budgets, and plans from this organization.
Aug 19, 2026·Board meeting agenda
Drug Utilization Review Board Agenda
The board meeting agenda focuses on the review of tentative agenda items including medications for ADHD, antipsychotics, postpartum depression, fibromyalgia, and immunomodulation. The board will evaluate and revise prior authorization criteria for various drug classes, including treatments for rheumatoid arthritis, Crohn's disease, oncology, and anti-obesity medications. Additionally, the agenda covers the proposal of new prior authorization criteria for cerebral adrenoleukodystrophy, chronic spontaneous urticaria, non-cystic fibrosis bronchiectasis, and phenylketonuria agents, alongside the presentation of retrospective drug utilization review outcomes and the selection of future intervention topics.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The committee meeting agenda covers the review and discussion of numerous new drug placements, including various medications for pain management, hypertension, and autoimmune conditions. Additionally, the committee will evaluate new drug classes such as Fibromyalgia agents, Immunomodulation agents for Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, and VMAT2 inhibitors. The agenda also includes discussions on new drugs to be added to existing PDL classes, such as Anti-Obesity medications, Asthma and Plaque Psoriasis treatments, Psoriatic Arthritis therapies, and long-acting Insulins.
Aug 11, 2026·Board meeting agenda
Mental Health Medication Advisory Committee Meeting Agenda
The committee meeting focuses on clinical reviews and prior authorization criteria for various medications. Specifically, the agenda includes discussions on safe use and prior authorization criteria for ADHD medications, including the addition of Atoncy, and antipsychotic medications, including the addition of step therapy for Bysanti. Additionally, the committee will review prior authorization criteria for postpartum depression agents, specifically for Zurzuvae. The meeting will also include a designated period for stakeholder input and open public comment.
May 20, 2026·Board meeting
Drug Utilization Review Board Meeting Agenda
The board meeting agenda focuses on the review of several pharmaceutical-related items, including revisions to prior authorization criteria for various medication categories such as immune globulins, oncology agents, epidermolysis bullosa treatments, and high-cost dosage forms. The meeting also involves establishing new prior authorization criteria for agents addressing cholestatic pruritus, chronic hand eczema, hereditary angioedema, macular telangiectasia, non-factor hemophilia prophylaxis, and Prader-Willi syndrome. Additionally, the agenda includes discussions on safe usage guidelines for ADHD and antipsychotic medications, as well as utilization data for T-cell receptor immunotherapy agents.
